medigraphic.com
ISSN 2007-6053 (Print)
Órgano oficial de difusión de los Hospitales Regionales de Alta Especialidad (HRAE)

2014, Number 1

<< Back Next >>

Evid Med Invest Salud 2014; 7 (1)

Carcinoid tumor diagnosed by 111 In-pentetreotide (OctreoScan)

Mendoza PL, Valero SR

Language: Spanish
References: 9
Page: 42-44
PDF size: 303.33 Kb.


ABSTRACT

Bronchopulmonary neuroendocrine tumors (BP-NET) comprise about 20% of all lung cancers; although they share structural, morphological, immunohistochemical and ultrastructural features, they are divided into 4 subgroups, namely: typical carcinoid tumor (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC). The clinical presentation includes cough, hemoptysis, and obstructive pneumonia, and varies depending on the pattern, site, size and growth. The 111In-pentetreotide (OctreoScan) is an octapeptide somatostatin analogue (there are five different types of somatostatin receptors) used for scintigraphic localization of primary neuroendocrine tumors (NET) and metastatic exhibiting somatostatin receptors.


REFERENCES

  1. Bombardieri E, Seregni E, Villano C, Chiti A, Bajetta EQ. Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. J Nucl Med Mol Imaging. 2004 Jun; 48 (2): 150-63.

  2. Cascini GL, Cuccurullo V, Tamburrini O, Rotondo A, Mansi L. Peptide imaging with somatostatin analogues: more than cancer probes. Curr Radiopharm. 2013 Mar; 6 (1): 36-40.

  3. Goldsmith SJ. Update on nuclear medicine imaging of neuroendocrine tumors. Future Oncol. 2009; 5 (1): 75-84. Doi: 10.2217/14796694.5.1.75.

  4. Rufini V, Calcagni ML, Baum RP. Images of neuroendocrine tumors. Semin Nucl Med. 2006; 36 (3): 228-47.

  5. Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM. Tumores broncopulmonares neuroendócrinos. Cáncer. 2008; 113 (1): 5-21. Doi: 10.1002/cncr.23542.

  6. Sorschag M, Malle P, Gallowitsch HJ. Nuclear medicine in NET. Wien Med Wochenschr. 2012; 162 (19-20): 416-22. doi: 10.1007/s10354-012-0130-z. Epub 2012, Jul 19.

  7. Carrasquillo JA, Chen CC. Molecular imaging of neuroendocrine tumors. Semin Oncol. 2010; 37 (6): 662-79. doi: 10.1053/j.seminoncol.2010.10.015.

  8. Gerasimou G, Moralidis E, Gotzamani-Psarrakou A.Somatostatin receptor imaging with (111)In-pentetreotide in gastro-intestinal tract and lung neuroendocrine tumors-Impact on targeted treatment. Hell J Nucl Med. 2010; 13 (2): 158-62.

  9. Virgolini I, Traub T, Novotny C, Leimer M, Füger B, Li SR et al. Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr Pharm Des. 2002; 8 (20): 1781-807.




2020     |     www.medigraphic.com